Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

NeoBenz(R) Micro

×

Overview

What is NeoBenz(R) Micro?



What does NeoBenz(R) Micro look like?



What are the available doses of NeoBenz(R) Micro?

Sorry No records found.

What should I talk to my health care provider before I take NeoBenz(R) Micro?

Sorry No records found

How should I use NeoBenz(R) Micro?

NeoBenz®

Micro,

NeoBenz®

Micro

NeoBenz®

Micro

should be used once or twice daily on the affected areas. Frequency of use should be adjusted to obtain the desired clinical response. If

u see medication or white residue on skin after application of

NeoBenz®

Micro

: 

NeoBenz®

Micro

NeoBenz®

Micro

NeoBenz®

Micro

NeoBenz®

Micro


What interacts with NeoBenz(R) Micro?

Sorry No Records found


What are the warnings of NeoBenz(R) Micro?

Sorry No Records found


What are the precautions of NeoBenz(R) Micro?

Sorry No Records found


What are the side effects of NeoBenz(R) Micro?

Sorry No records found


What should I look out for while using NeoBenz(R) Micro?


What might happen if I take too much NeoBenz(R) Micro?

If excessive scaling, erythema or edema occurs, the use of these preparations should be discontinued. To hasten resolution of the adverse effects, cool compresses may be used. After symptoms and signs subside, a reduced dosage schedule may be cautiously tried if the reaction is judged to be due to excessive use and not allergenicity.


How should I store and handle NeoBenz(R) Micro?

Store at controlled room temperature 20-25C (68-77F). Excursions permitted to 15-30C (59-86F). [See current USP]Dispense in a tight, light-resistant container to protect from light and moisture.Store at controlled room temperature 20-25C (68-77F). Excursions permitted to 15-30C (59-86F). [See current USP]Dispense in a tight, light-resistant container to protect from light and moisture.Allergenic extracts are supplied with units listed as: Weight/volume (W/V), Protein Nitrogen Units (PNU/ml), Allergy Units (AU/ml) or Bioequivalent Allergy Units (BAU/ml). Sizes:Diagnostic Scratch: 5 ml dropper application vialsDiagnostic Intradermal: 5 ml or 10 ml vials.Therapeutic Allergens: 5 ml, 10 ml, 50 ml multiple dose vials.Allergenic extracts are supplied with units listed as: Weight/volume (W/V), Protein Nitrogen Units (PNU/ml), Allergy Units (AU/ml) or Bioequivalent Allergy Units (BAU/ml). Sizes:Diagnostic Scratch: 5 ml dropper application vialsDiagnostic Intradermal: 5 ml or 10 ml vials.Therapeutic Allergens: 5 ml, 10 ml, 50 ml multiple dose vials.Allergenic extracts are supplied with units listed as: Weight/volume (W/V), Protein Nitrogen Units (PNU/ml), Allergy Units (AU/ml) or Bioequivalent Allergy Units (BAU/ml). Sizes:Diagnostic Scratch: 5 ml dropper application vialsDiagnostic Intradermal: 5 ml or 10 ml vials.Therapeutic Allergens: 5 ml, 10 ml, 50 ml multiple dose vials.Allergenic extracts are supplied with units listed as: Weight/volume (W/V), Protein Nitrogen Units (PNU/ml), Allergy Units (AU/ml) or Bioequivalent Allergy Units (BAU/ml). Sizes:Diagnostic Scratch: 5 ml dropper application vialsDiagnostic Intradermal: 5 ml or 10 ml vials.Therapeutic Allergens: 5 ml, 10 ml, 50 ml multiple dose vials.Allergenic extracts are supplied with units listed as: Weight/volume (W/V), Protein Nitrogen Units (PNU/ml), Allergy Units (AU/ml) or Bioequivalent Allergy Units (BAU/ml). Sizes:Diagnostic Scratch: 5 ml dropper application vialsDiagnostic Intradermal: 5 ml or 10 ml vials.Therapeutic Allergens: 5 ml, 10 ml, 50 ml multiple dose vials.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of controlbinding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81%).

(

)

General

– For external use only. Avoid contact with eyes and mucous membranes. If severe irritation develops, discontinue use and institute appropriate therapy.

SEE WARNINGS

Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).